Literature DB >> 21291879

Impaired GFR is the most important determinant for FGF-23 increase in chronic kidney disease.

Guido Filler1, Daisy Liu, Shih-Han Susan Huang, Shelley Casier, Luan A Chau, Joaquín Madrenas.   

Abstract

OBJECTIVES: It is unclear whether fibroblast growth factor-23 (FGF-23) increases in response to phosphate accumulation or to decrease clearance in chronic kidney disease (CKD) as is the case with other low molecular weight proteins such as cystatin C (CysC). DESIGN AND METHODS: This cross-sectional study measured serum FGF-23, CysC, and other serum markers of bone metabolism in 69 patients, aged 18 months-24 years, with various stages of CKD (eGFR=11-214mL/min).
RESULTS: FGF-23 levels were significantly correlated with CysC and parathyroid hormone levels (PTH) on univariate non-linear regression analysis. In multivariate linear regression analysis, log (CysC) (β=0.660, p<0.0001), log (PTH) (β=0.038, p=0.37), and phosphate (β=0.222, p=0.028) explained 69.1% of the variance of FGF-23.
CONCLUSIONS: CysC had the largest unique contribution to FGF-23 variance in this model, supporting the hypothesis that renal clearance may be the most responsible factor for elevated FGF-23 levels in early stages of CKD.
Copyright © 2011 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21291879     DOI: 10.1016/j.clinbiochem.2011.01.009

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  10 in total

1.  p38MAPK controls fibroblast growth factor 23 (FGF23) synthesis in UMR106-osteoblast-like cells and in IDG-SW3 osteocytes.

Authors:  F Ewendt; M Föller
Journal:  J Endocrinol Invest       Date:  2019-06-14       Impact factor: 4.256

2.  Fibroblast growth factor 23 in patients undergoing peritoneal dialysis.

Authors:  Tamara Isakova; Huiliang Xie; Allison Barchi-Chung; Gabriela Vargas; Nicole Sowden; Jessica Houston; Patricia Wahl; Andrew Lundquist; Michael Epstein; Kelsey Smith; Gabriel Contreras; Luis Ortega; Oliver Lenz; Patricia Briones; Phyllis Egbert; T Alp Ikizler; Harald Jueppner; Myles Wolf
Journal:  Clin J Am Soc Nephrol       Date:  2011-09-08       Impact factor: 8.237

3.  The effects of iron on FGF23-mediated Ca-P metabolism in CKD patients.

Authors:  Serpil Muge Deger; Yasemin Erten; Ozge Tugce Pasaoglu; Ulver Boztepe Derici; Kadriye Altok Reis; Kursad Onec; Hatice Pasaoglu
Journal:  Clin Exp Nephrol       Date:  2012-11-20       Impact factor: 2.801

4.  Fibroblast growth factor-23 and calcium phosphate product in young chronic kidney disease patients: a cross-sectional study.

Authors:  Abeer Yasin; Daisy Liu; Luan Chau; Joaquín Madrenas; Guido Filler
Journal:  BMC Nephrol       Date:  2013-02-17       Impact factor: 2.388

5.  Applicability of fibroblast growth factor 23 for evaluation of risk of vertebral fracture and chronic kidney disease-mineral bone disease in elderly chronic kidney disease patients.

Authors:  Eiichiro Kanda; Masayuki Yoshida; Sei Sasaki
Journal:  BMC Nephrol       Date:  2012-09-26       Impact factor: 2.388

6.  Plasma FGF23 levels increase rapidly after acute kidney injury.

Authors:  Marta Christov; Sushrut S Waikar; Renata C Pereira; Andrea Havasi; David E Leaf; David Goltzman; Paola D Pajevic; Myles Wolf; Harald Jüppner
Journal:  Kidney Int       Date:  2013-05-08       Impact factor: 10.612

7.  Deviations from the expected relationship between serum FGF23 and other markers in children with CKD: a cross-sectional study.

Authors:  Daisy Liu; Ana Catalina Alvarez-Elías; Brooke Wile; Vladimir Belostotsky; Guido Filler
Journal:  BMC Nephrol       Date:  2017-06-28       Impact factor: 2.388

Review 8.  Renal biomarkers in cats: A review of the current status in chronic kidney disease.

Authors:  Thirawut Kongtasai; Dominique Paepe; Evelyne Meyer; Femke Mortier; Sofie Marynissen; Lisa Stammeleer; Pieter Defauw; Sylvie Daminet
Journal:  J Vet Intern Med       Date:  2022-02-26       Impact factor: 3.333

9.  Relationship between FGF 23, SDMA, Urea, Creatinine and Phosphate in Relation to Feline Chronic Kidney Disease.

Authors:  Simona Grelová; Martina Karasová; Csilla Tóthová; Terézia Kisková; Darina Baranová; Branislav Lukáč; Mária Fialkovičová; Alena Micháľová; Lukáš Kunay; Miroslav Svoboda
Journal:  Animals (Basel)       Date:  2022-08-31       Impact factor: 3.231

Review 10.  Mineral and Bone Disorders After Kidney Transplantation.

Authors:  Chandan Vangala; Jenny Pan; Ronald T Cotton; Venkat Ramanathan
Journal:  Front Med (Lausanne)       Date:  2018-07-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.